862 related articles for article (PubMed ID: 28139263)
1. JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W; King BA
J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors in dermatology: A systematic review.
Shreberk-Hassidim R; Ramot Y; Zlotogorski A
J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
6. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
8. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
9. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
11. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
[TBL] [Abstract][Full Text] [Related]
12. The emerging safety profile of JAK inhibitors in rheumatic disease.
Winthrop KL
Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
[TBL] [Abstract][Full Text] [Related]
13. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
14. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
16. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Peterson D; Damsky W; King B
J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797
[No Abstract] [Full Text] [Related]
17. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Muddebihal A; Khurana A; Sardana K
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
[TBL] [Abstract][Full Text] [Related]
19. Journal club: New small molecules for atopic dermatitis management.
Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E
Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077
[No Abstract] [Full Text] [Related]
20. JAK inhibitors in chronic plaque psoriasis: What is known so far.
Plachouri KM; Georgiou S
Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
